A recent pause in U.S. sales of Varipulse is hampering the company’s bid to catch up in one of the industry’s fastest-growing ...

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby ...

Johnson & Johnson begins a two-week trial on Feb. 18 over its plan to end tens of thousands of lawsuits filed by women or ...

Johnson & Johnson is looking to sell its Cerenovus stroke therapy business, according three unnamed people "with knowledge of ...

Johnson & Johnson aims to streamline operations by selling its stroke care business, Cerenovus, valued at $1B+.

J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected ...

Read about the spot won by J&J Worldwide Services on a U.S. Army multiple-award contract to provide repair, renovation and ...

B Health and two safety-net hospitals want to help the government prove that drugmakers are required to give upfront discounts on 340B drugs.

Two U.S. federal health agencies have objected to Johnson & Johnson's $10 billion proposed settlement of tens of thousands of ovarian cancer lawsuits, saying that resolving those cases in bankruptcy ...

weak medical device sales in China, and potential generic competition for its drug Stelara. Senior Health Reporter Anjalee Khemlani joins Market Domination to break down J&J's latest quarter.

"Darzalex continues to be a pillar brand with respect to performance," said J&J's Wolk in an interview, noting that sales from Shockwave Medical also helped drive growth.